GlobeNewswire Inc.·3h ago·NaGlucotrack Charts Path to FDA Trials as Q1 Loss Narrows 37%Glucotrack ($GCTK) submits FDA application for implantable glucose monitor, cuts losses 37% YoY to $4.3M in Q1 2026. GCTKFDA approvalclinical trial
GlobeNewswire Inc.··Na